Off-label prescribing;La prescription «off-label»

Revue Medicale Suisse

Volumn 4, Issue 165, 2008, Pages 1661-1665

  Blondon, Katherine ^a   Desmeules, Jules ^b   Vogt Ferrier, Nicole ^b   Besson, Marie ^b   Kondo Oestreicher, Mitsuko ^b   Dayer, Pierre ^b  

^a SERVICE DE MÉDECINE INTERNE GÉNÉRALE   (Switzerland)

^b Service de Pharmacologie et Toxicologie Cliniques   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

BOTULINUM TOXIN A; PROMETHAZINE;

DRUG EFFICACY; DRUG SAFETY; ECONOMIC ASPECT; HEALTH INSURANCE; MALPRACTICE; OFF LABEL DRUG USE; PHYSICIAN; PRESCRIPTION; REVIEW; SWITZERLAND; ATTITUDE TO HEALTH; CLINICAL PRACTICE; DRUG LABELING; ETHICS; HUMAN; INFORMED CONSENT; LEGAL ASPECT; SAFETY;

DRUG LABELING; DRUG PRESCRIPTIONS; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HUMANS; INFORMED CONSENT; PHYSICIAN'S PRACTICE PATTERNS; SAFETY; SWITZERLAND;

EID: 48349147806     PISSN: 16609379     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (30)

1. Russell ME, Friedman MI, Mascioli SR, et al. Off-label use : An industry perspective on expanding use beyond approved indications. J Interv Cardiol 2006;19:432-8.
2. Weeks AD, Fiala C, Safar P. Misoprostol and the debate over off-label drug use. BJOG 2005;112:269-72.
3. ** Recommandations de l'Association des pharmaciens cantonaux suisses et de Swissmedic au sujet de l'utilisation des médicaments au sens de l'off label use (24 juillet 2006). www.swissmedic.ch/files/pdf/Off- label_ Use_Schlusspapier-F.pdf
4. ** Radley DC, Finkelstein SN, Stafford RS. Off-label prescribing among office-based physicians. Arch Intern Med 2006;166:1021-6.
5. Cras A, Conscience MA, Rajzbaum G, et al. Off-label prescribing in a French hospital. Pharm World Sci 2007;29:97-100.
6. British thoracic society scottish intercollegiate guidelines network. British guideline on the management of asthma Thorax 2008;63(Suppl. 4):iv1-121.
7. Shah SS, Hall M, Goodman DM, et al. Off-label drug use in hospitalized children. Arch Pediatr Adolesc Med 2007;161:282-90.
8. Vonnez JL. La Suisse s'inquiète de la prescription «off label» en pédiatrie. Med Hyg 2003;61:316.
9. Benjamin DK, Smith PB, Murphy MD, et al. Peer-reviewed publication of clinical trials completed for pediatric exclusivity. JAMA 2006;296:1266-73.
10. Di Paolo ER, Stoetter H, Cotting J, et al. Unlicensed and off-label drug use in a Swiss paediatric university hospital. Swiss Med Wkly 2006;136:218-22.
11. Swissmedic - Médicaments pour enfants : état des lieux. Déc 2006. www.swissmedic.ch/files/pdf/Merkblatt_ Arzneimittel_f%FCr_Kinder-F.pdf
12. McCowan C, Hoskins G, Neville RG. Clinical symptoms and «off-label» prescribing in children with asthma. Br J Gen Pract 2007;57:220-2.
13. Jonville-Béra AP, Béra F, Autret-Leca E. Are incorrectly used drugs more frequently involved in adverse drug reactions ? A prospective study. Eur J Clin Pharmacol 2005;61:231-6. PMID : 15824917.
14. Laroche ML, Charmes JP, Nouaille Y, et al. Is inappropriate medication use a major cause of adverse drug reactions in the elderly ? Br J Clin Pharmacol 2007;63: 177-86.
15. Casali PG ; Executive Committee of ESMO. The «off-label» use of drugs in oncology : A position paper by the European society for medical oncology (ESMO). Ann Oncol 2007;18:1923-5.
16. Stafford RS. Regulating «off-label» drug use - rethinking the role of the FDA. N Engl J Med 2008; 358:1427-9.
17. Wagner M. Off-label use of misoprostol in obstetrics : A cautionary tale. BJOG 2005;112:266-8.
18. Novack GD. Pharmacotherapy for the treatment of choroidal neovascularization due to age-related macular degeneration. Annu Rev Pharmacol Toxicol 2008;48: 61-78.
19. Comparison of age-related macular degeneration treatments trials (CATT). Déc 2007. www.med.upenn. edu/cpob/studies/CATT.shtml
20. Compendium suisse des médicaments 2008, online edition. Documed.
21. Heinen F, Molenaers G, Fairhurst C, et al. European consensus table 2006 on botulinum toxin for children with cerebral palsy. Eur J Paediatr Neurol 2006;10:215-25.
22. US Food and drug administration. Early communication about an ongoing safety review botox and botox cosmetic (Botulinum toxin type A) and myobloc (Botulinum toxin type B). www.fda.gov/cder/drug/early_comm/ botulinium_toxins. htm
23. Health Canada reviewing issue of distant toxin spread potentially associated with Botox and Botox cosmetic. www.hc-sc.gc.ca/ahc-asc/media/ advisories-avis/_2008/2008_32_e.html
24. * Parrish R, Sternberg P. Does «off-label» mean off limits for patient care ? Am J Ophthalmol 2007;143: 853-5.
25. American academy of pediatrics committee on drugs. Uses of drugs not described in the package insert («off-label» uses). Pediatrics 2002;110:181-3.
26. Jeste DV, Blazer D, Casey D, et al. ACNP white paper : Update on use of antipsychotic drugs in elderly persons with dementia. Neuropsychopharmacology 2008;33:957-70.
27. Tribunal Fédéral K 147/06.
28. Goldberg DJ. Legal ramifications of «off-label» filler use. Dermatol Ther 2006;19:189-93.
29. ** Steinman MA, Bero LA, Chren MM, et al. Narrative review : The promotion of gabapentin : An analysis of internal industry documents. Ann Intern Med 2006;145:284-93.
30. Minzenberg MJ, Carter CS. Modafinil : A review of neurochemical actions and effects on cognition. Neuropsychopharmacology 2008;33:1477-502.